Competitive Analysis of Insulin Pumps Market

Key Players

Competitive Landscape

Competition across the insulin pumps market centers on form-factor miniaturization, multi-sensor closed-loop interoperability, and specialty pharmacy channel contracting. Pure-play patch leader Insulet Corporation and automated tethered leaders Medtronic plc, Tandem Diabetes Care Inc., Beta Bionics Inc., and Ypsomed Holding AG capture over 90% of global commercial revenue through proprietary closed-loop algorithms (SmartAdjust, SmartGuard, Control-IQ+, iLet/3D Intelligence, and mylife Loop). European and Asian specialists F. Hoffmann-La Roche Ltd compete through connected Accu-Chek diabetes ecosystems, while MicroTech Medical (Hangzhou) Co. Ltd. advances ultra-light 23-gram Equil semi-disposable patch pumps, alongside Terumo Corporation and SOOIL Developments Co. Ltd. expanding open Bluetooth protocol compatibility, and Embecta Corp. anchoring adjacent diabetes injection disposables.

Convergence toward hybrid tubeless-tethered modularity and Type 2 diabetes label expansions with corporate pure-play spin-offs defines manufacturer strategy from 2025 onward. Traditional tethered pump makers are launching wearable patch options to challenge Insulet's Omnipod franchise, which generated USD 2,674.0 million in 2025 and USD 1,554.3 million in the first half of 2026 across more than 600,000 active users. In August 2026, Tandem Diabetes Care submitted an FDA 510(k) for a Tandem Mobi tubeless infusion site after achieving USD 1,014.7 million in 2025 sales, while Beta Bionics won FDA clearance for its Mint patch pump in September 2026. Concurrently, Medtronic advanced the separation of its USD 3,112 million Diabetes business into MiniMed Group, and Ypsomed transferred its CHF 175.3 million mylife YpsoPump business to TecMed AG.

Company developments mapped to drivers, trends and opportunities (2026-2036)

Development Driver Trend Opportunity
September 2026: Beta Bionics received FDA 510(k) clearance for its Mint patch pump and unveiled 3D Intelligence. Many MDI patients refuse pumps due to visible tubing and complex carbohydrate counting. Bionic pancreas developers combine zero-carb-counting algorithms with two-piece modular patch pods. Pharmacy-exclusive Q1 2027 Mint rollout backed by 1.5M-unit capacity targets adult MDI switchers.
August 2026: Tandem Diabetes Care submitted an FDA 510(k) for a Tandem Mobi tubeless infusion site capability. Patients want the flexibility to switch between tethered infusion sets and on-body patch wear. Traditional durable pump manufacturers engineer hybrid micro-pumps supporting both tubed and tubeless sites. Dual-wear Mobi accessories and CE Mark Type 2/pregnancy approvals expand international market share.
August 2026: Insulet reported H1 2026 Omnipod revenue of USD 1,554.3M and launched Omnipod 5 in the Middle East and Spain. Over-the-counter pharmacy fulfillment removes upfront DME capital barriers for tubeless AID. Patch-pump leaders expand international country launches (20+ countries) and 100 mg/dL target algorithms. Pivotal EVOLVE Type 2 trials and FreeStyle Libre 3 Plus integration unlock broader adult cohorts.
June 2026: Medtronic reported USD 3,112M FY26 Diabetes revenue (+12.9%) and cleared MiniMed Flex (K253743),. High-dose Type 1 and Type 2 patients require 300-unit capacity and 7-day extended infusion sets. Diversified medtech conglomerates spin off dedicated Diabetes pure-play entities (MiniMed Group). Standalone capital allocation accelerates next-generation MiniMed Flex micro-pump commercialization.

Source: Future Market Insights, Insulin Pumps Market Report, 2026-2036.

Recent FDA clearances for two-piece modular patch pumps and 100 mg/dL target closed-loop algorithms with Type 2 diabetes indications confirm that pump therapy is moving into mainstream primary-care endocrinology. Suppliers that combine pharmacy-benefit pod pricing with multi-sensor CGM choice are projected to capture the highest share of new MDI conversions.

How are key market participants positioned in the insulin pumps market?

Medtronic plc and Tandem Diabetes Care Inc. with Beta Bionics Inc. and Ypsomed Holding AG lead in automated closed-loop tethered and hybrid micro-pumps. Insulet Corporation dominates tubeless automated patch pods while F. Hoffmann-La Roche Ltd, MicroTech Medical (Hangzhou) Co. Ltd., and Terumo Corporation supply semi-disposable micropumps, and SOOIL Developments Co. Ltd. and Embecta Corp. provide interoperable controllers and delivery disposables.

What qualification or purchasing requirements matter most to prospective buyers?

Endocrinology clinic directors and health-plan pharmacy committees require verified clinical trial increases in Time in Range (70 to 180 mg/dL above 65% to 70%) and compatibility with both Dexcom G7 15-Day and Abbott FreeStyle Libre 3 Plus sensors with zero-upfront-cost specialty pharmacy adjudication.

Which product or application capabilities distinguish the leading companies?

Insulet differentiates through its fully disposable waterproof Omnipod 5 pod with on-pod SmartAdjust automation. Beta Bionics stands out through meal-announcement-free bionic pancreas dosing and its newly cleared Mint patch pump, while Medtronic and Tandem excel in 7-day extended infusion sets and dual-mode tubed/tubeless micro-pumps.

How does geographic reach differ among the key market players?

Medtronic plc and Insulet Corporation with Tandem Diabetes Care Inc. and F. Hoffmann-La Roche Ltd operate across North America, Europe, and the Middle East (with Omnipod 5 active in 20+ countries). Ypsomed/TecMed anchors European mylife Loop supply, while Terumo Corporation, SOOIL Developments Co. Ltd., and MicroTech Medical lead across Japan, South Korea, and China.

Representative Company Overview

Company Positioning Verified Development
Medtronic plc Global diabetes technology leader supplying MiniMed 780G closed-loop systems, Extended 7-day infusion sets, and MiniMed Flex. Reported USD 3,112M FY26 Diabetes revenue (+12.9%) in June 2026 and secured FDA 510(k) K253743 for MiniMed 780G and Flex in March 2026.
Insulet Corporation (Omnipod) Global pure-play leader in tubeless wearable patch-pump therapy (Omnipod 5 automated insulin delivery and Omnipod DASH). Generated USD 2,674.0M FY2025 and USD 1,554.3M H1 2026 Omnipod revenue across >600,000 active users and launched Omnipod 5 in 5 Middle East markets.
Tandem Diabetes Care Inc. Manufacturer of t:slim X2 and ultra-compact Tandem Mobi insulin pumps powered by Control-IQ+ automated dosing technology. Surpassed USD 1,014.7M in FY2025 sales and submitted an FDA 510(k) in Q2 2026 for a Tandem Mobi tubeless infusion site capability,.
F. Hoffmann-La Roche Ltd Swiss healthcare leader offering the Accu-Chek Solo tubeless micropump, Accu-Chek Spirit Combo, and SmartGuide CGM in Europe. Secured CE Mark for its AI-enabled Accu-Chek SmartGuide CGM with 2-hour glucose prediction integrated with its European diabetes platform.
Beta Bionics Inc. Commercial-stage developer of the iLet Bionic Pancreas and Mint patch pump utilizing adaptive autonomous dosing algorithms. Received FDA 510(k) clearance for the Mint patch pump in September 2026, unveiled 3D Intelligence, and surpassed 40,000 real-world iLet users.
Embecta Corp. Global diabetes injection disposable leader (spun off from BD) holding FDA-cleared 300-unit Type 2 disposable patch-pump technology. Maintains FDA 510(k) clearance for a 300-unit wearable patch pump while prioritizing core pen-needle and GLP-1 delivery cash flows.
SOOIL Developments Co. Ltd. South Korean precision insulin pump manufacturer supplying the BLE 5.0 Diabecare DANA-i interoperable closed-loop pump. Supplies 300-unit DANA-i interoperable pumps across South Korean NHIS and European CamAPS FX / Diabeloop hybrid closed-loop programs.
MicroTech Medical (Hangzhou) Co. Ltd. Chinese diabetes device innovator manufacturing the ultra-light 23-gram Equil semi-disposable tubeless patch insulin pump. Rolled out its March 2026 V10 diabetes management ecosystem update pairing the Equil tubeless patch pump with AiDEX CGM sensors.
Terumo Corporation Japanese medical technology manufacturer producing the detachable tubing-free MEDISAFE WITH patch insulin pump. Published February 2026 engineering updates on its stepper-motor MEDISAFE WITH patch pump and Diabeloop closed-loop development in Japan.

Research Methodology

Market sizing for the insulin pumps market combined primary interviews with adult and pediatric endocrinologists and certified diabetes care educators with pharmacy benefit managers and top-down and bottom-up corporate revenue triangulation. Active user-to-value modeling reconciles installed global tethered and patch pump patient bases (1.36M to 1.48M active users in 2026) against audited FY2025 and FY2026 manufacturer hardware and pod/infusion-set revenues from 2026 to 2036. Final market figures isolate external insulin infusion pumps and disposable patch pods with infusion sets while strictly excluding standalone continuous glucose monitoring sensors and insulin vials.

Future Market Insights

Insulin Pumps Market